Aerobic glycolysis is the most important metabolic feature of cancer cells. It can not only provide energy for the continuous proliferation of cancer cells but also the metabolites of the glycolysis pathway can participate in other metabolic pathways and serve as raw materials for the synthesis of biological macromolecules. Therefore, understanding the glycolytic state of cancer cells is of great significance for the regulation of glucose metabolism in cancer cells and the development of new drugs targeting glycolysis in cancer cells.
CD BioGlyco can provide a comprehensive real-time analysis of cancer glycolytic pathways based on the MOPCGM platform. We can help customers accurately analyze the metabolites involved in the glycolytic pathway, the activities of metabolic enzymes, and the expression, modification, and interaction of glycolytic-related proteins.
Cancer glycolysis genomics analysis specifically targets the glycolytic pathway. Through our genomics platform, we help customers obtain information on glycolysis-related gene mutations and chromatin rearrangements.
The concentration of glycolytic metabolites is an essential parameter to study the glycolytic pathway of cancer cells. We use metabolomics technology to provide customers with metabolite concentration data across the entire process of glycolysis in cancer cells. Different sources and different treatments for cancer cells have different glycolytic metabolic states and different metabolite concentrations, and their differences can identify factors that affect cancer cell glycolysis.
Glycolytic metabolic flux analysis is dynamic monitoring of the glycolytic pathway. Based on metabolic fluxomics technology, it can help customers understand the consumption and production rates of metabolites in the glycolytic pathway without changing the concentration of metabolites in the glycolytic pathway.
Glycolytic enzyme analysis of cancer cells provides a global view of glycolytic pathways at the protein level. Based on the proteomics platform, we use a variety of technologies to provide customers with the analysis of the expression, localization, modification, and interaction of enzymes related to the glycolytic pathway in cancer cells.
CD BioGlyco provides multi-omics analysis for cancer cell glycolysis, including genomics, proteomics, metabolomics, and metabolic fluxomics, to help customers gain a comprehensive understanding of cancer cell glycolysis pathways. Our experienced teams of scientists, researchers, and technicians provide fast turnaround, high-quality services at competitive prices for worldwide customers. Our customers have direct access to our staff and prompt feedback on their inquiries. If you are interested in our services, please contact us for more details.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.